|D016638||Critical Illness NIH||0.13|
|D003141||Communicable Diseases NIH||0.07|
There is one clinical trial.
High risk outpatient adult males with a confirmed SARS-CoV-2 infection will be included in the study. Patients will be randomized to receive Enzalutamide with standard of care (SOC) or SOC alone. Enzalutamide will be administered daily p.o. from Day 1 to Day 28 or until confirmed negativization of Nasopharyngeal swap (NPS) Polymerase chain reaction (PCR) (2 consecutive negative samples), whichever occurs first.
Description: efficacy of Enzalutamide in decreasing the nasopharyngeal swap SARS-CoV-2 viral load until negativizationMeasure: Efficacy of Enzalutamide Time: 28 days
Description: Efficacy of Enzalutamide in controlling disease progression of SARS-CoV-2 viral loadMeasure: Disease progression Time: 28 days
Description: Evaluation of Enzalutamide tolerability in terms of incidence and severity grade of side effectsMeasure: Tollerability of Enzalutamide Time: 28 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports